Reduced Risk Across Multiple Cardiometabolic Risk Factors With OLZ/SAM Compared With Olanzapine: Results From a 24-Week Phase 3 Study

Authors :: Christine Graham
Arielle D. Stanford
Ying Jiang
Sergey Yagoda
David McDonnell
Christoph U. Correll
Craig Hopkinson
Sarah C. Akerman
Lauren DiPetrillo
Evan Stein
Source :: Biological Psychiatry. 89:S339
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Cardiometabolic risk
Oncology
Olanzapine
Reduced risk
medicine.medical_specialty
business.industry
Internal medicine
Medicine
Phases of clinical research
business
Biological Psychiatry
medicine.drug

Full Text Access

Tools